BTIG Reiterates Buy Rating on DexCom (DXCM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to BTIG Reiterates Buy Rating on DexCom (DXCM)
October 25, 2024 6:25 AM EDT
Bernstein SocGen Group analyst Lee Hambright raised the price target on DexCom (NASDAQ: DXCM) to $86.00 (from $82.00) while maintaining a Market Perform rating.
The analyst comments "In-line quarter. Revenue grew 3% organic, landing at the high-end of the reduced guidance range that DXCM set on the Q2 call (1% to 3%). U.S. sales declined -2% organic,... More
October 24, 2024 4:42 PM EDT
After-Hours Stock Movers:
Capri Holdings (NYSE: CPRI) shares fell 48% after a judge blocked its deal to merge with Tapestry (NYSE: TPR), a victory for the FTC. Tapestry shares gained.
DexCom (NASDAQ:... More
October 24, 2024 4:16 PM EDT
DexCom (NASDAQ: DXCM) reported third-quarter earnings that surpassed analyst expectations, but the company's stock plummeted 16% as revenue growth slowed significantly.
The continuous glucose monitoring systems maker posted adjusted earnings per share of $0.45, beating the analyst consensus of $0.43. Revenue for the quarter came in at... More
October 24, 2024 4:04 PM EDT
DexCom (NASDAQ: DXCM) reported Q3 EPS of $0.45, $0.02 better than the analyst estimate of $0.43. Revenue for the quarter came in at $994.2 million versus the consensus estimate of $990.44 million.
GUIDANCE:
DexCom sees FY2024 revenue of $4-4.05 billion, versus the consensus of $4.01... More
